Q-omics provides the consensus-scored ZFY profile across patient tissues and cancer cell-line models. ZFY expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ZFY is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, ZFY RNA expression shows 9,590 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRP, and TGCT as cancer lineages where ZFY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFY survival associations across molecular data types. ZFY RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFY RNA expression–survival associations across cancer types. High ZFY expression shows unfavorable associations in UCEC, UCS and THCA, but favorable associations in HNSC, UVM and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for ZFY RNA expression.
This table summarizes ZFY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZFY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFY shows lower tumor expression in KIRP, KICH, THCA, HNSC, STAD and LUSC. The KIRP box plot shows higher ZFY RNA expression in normal versus tumor tissue (log2 FC = −1.621, t-test p < 0.001).
This table shows molecular features associated with ZFY in patient tissues and cancer cell lines. In patient samples, ZFY shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OESOPHAGUS.
